Printer Friendly

CANCER TUMOR MARKER PROCEEDS TO CLINICAL TRIALS

 EDMONTON, Alberta, April 15 /PRNewswire/ -- The Alberta Cancer Board and Briana Bio-Tech Inc. (Vancouver: BIA) today announced approval to proceed with clinical trials of the AMDL DR-70 (TM) Tumor Marker Test, to confirm its reliability in detecting cancer tumors and indicating quantitative levels of tumor marker in patients.
 The Research Ethics Committee, Alberta Cancer Board, has confirmed that clinical trials will be conducted at the Cross Cancer Institute (CCI) in Edmonton, Alberta, under the auspices of the Alberta Cancer Board. The focus of these trials will be lung cancer patients.
 There is currently no broad-based tumor marker test available for lung cancer, one of the leading causes of adult deaths from cancer.
 Two hundred and fifty patients with demonstrated active lung cancer will be enrolled in the study, together with a control group of 100 volunteers with no clinical evidence of the disease. Sera testing will be done to confirm the reliability of the DR-70 test, and its usefulness in tracking tumor response to treatment and providing early indication of disease recurrence.
 The DR-70 test, a non-invasive biochemical probe, has shown early indications of being one of the most sensitive tumor marker tests currently being used or tested, and has demonstrated applications for several types of cancer. Preliminary results show the test to be both reliable and specific at indicating quantitative levels of tumor marker in the patient's blood serum.
 Briana Bio-Tech Inc. is of the opinion that DR-70 is a pan tumor marker. Therefore, clinical trials focusing on DR-70 effectiveness in detecting other types of cancer are expected to run concurrently with the lung cancer study. Commercial marketing specific to each application will follow upon successful demonstration of reliability. In an earlier pre-clinical study, DR-70 accurately identified the presence of 22 different types of cancer, indicating its potential as a pan tumor marker.
 Briana Bio-Tech Inc., through its wholly owned subsidiary AMDL Canada Inc., owns the exclusive Canadian marketing rights to systems developed by AMDL Inc. of Pasadena, Calif., for early detection and monitoring of a broad range of cancers. In addition, AMDL Canada Inc. controls options to acquire the marketing rights for all other countries outside the United States. Briana Bio-Tech Inc. is a publicly owned company whose shares are listed for trading on the Vancouver Stock Exchange.
 Background
 The AMDL DR-70 Tumor Marker Test is the result of more than twenty years of research by Drs. Guerrero and Rounds of AMDL Inc. in Pasadena.
 The technology is based on the detection of sub-microscopic ring- shaped particles (known as RSP) which appear to be shed in detectable quantities by malignant cells both in the laboratory and in the human body. RSP has been studied by many researchers and, although its exact function is still not clearly understood by the medical community, its potential in the detection, monitoring and treatment of cancer has been identified and will be the subject of further Alberta Cancer Board research.
 AMDL DR-70 is an inexpensive, non-invasive biochemical process performed on the blood sample of a patient. It is also relatively simple to manufacture and use. Its two most significant attributes are the speed at which it responds to any change in levels of cance and relative amount of cancer in the body. The test's ability to detect changes in levels of RSP is significant -- preliminary tests indicate the new test system is sensitive to change within eight to 10 days of surgery or other treatments which reduce tumor tissue.
 The sensitivity of the test indicates its potential use to assist doctors to measure and evaluate the effectiveness of treatment -- making AMDL DR-70 a significant new partner in effectively managing patient treatment.
 Tumor markers currently being used have proven to be generally restricted to the detection of specific cancers. For example, the CA-125 Marker is used to test for ovarian cancer, and the PSA Marker is used to test for carcinomas of the prostrate.
 Preliminary studies of the AMDL DR-70 test indicate its ability to accurately detect a broad range of cancers (22 different kinds of cancers have been tested to date), and to detect tumors in very early stages of development. Preliminary research of the test system has shown detection of cancer in patients four to 10 months prior to the emergence of symptoms measurable by standard clinical procedures.
 -0- 4/15/93
 /EDITOR'S NOTE: Guerrero and Rounds will be available for telephone or in-person interviews. Contact Caroline Nevin at 403-426-3610, to arrange


interviews./
 /CONTACT: John Tkachuk, president of Briana Bio-Tech, 403-423-1038; or Kate Hildebrandt of Alberta Cancer Board, 403-482-9381; or Janet Partington, clinical trial coordinator of Cross Cancer Institute, 403-497-6793 (pager)/
 (BIA.)


CO: Briana Bio-Tech Inc.; Albeta Cancer Board; Cross Cancer
 Institute ST: Alberta IN: MTC SU:


BP -- LA030 -- 6463 04/15/93 16:49 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 15, 1993
Words:794
Previous Article:ARCO & L.A. CLIPPERS HOST YOUTH RALLY SALUTING 'NEIGHBORHOOD PRIDE' PROGRAM THAT REFURBISHED 21 CITY PLAYGROUNDS
Next Article:FLEET FINANCIAL GROUP EXPANDS SPONSORSHIP OF REGIONAL NEWS MAGAZINES PRODUCED BY BROADCAST NEWS NETWORKS
Topics:


Related Articles
AMDL BEGINS CLINICAL TRIAL OF CANCER BLOOD TEST IN GERMANY
Millennium Initiates Combination Oncology Trials of MLN341 with Taxotere(R); Furthers Aggressive Clinical Development Program of Investigational...
Immunomedics obtains lymphoma antibody patent.
igeneon presents at 'International Society for Biological Therapy of Cancer' (iSBTc) 18th Annual Meeting; * Lecture on disseminated tumor cells as...
Introgen's INGN 241 Enhances Anti-Tumor Effects of Herceptin(R) in Preclinical Studies.
Cytokinetics Announces Clinical and Non-Clinical Results for Ispinesib at the 2005 Annual AACR-NCI-EORTC Meeting.
Introgen's ADVEXIN p53 Therapy Demonstrates Clinical Benefit in Inherited Cancer.
Introgen's ADVEXIN p53 Therapy Demonstrates Clinical Benefit in Inherited Cancer.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters